These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. New approaches from nanomedicine for treating leishmaniasis. Gutiérrez V; Seabra AB; Reguera RM; Khandare J; Calderón M Chem Soc Rev; 2016 Jan; 45(1):152-68. PubMed ID: 26487097 [TBL] [Abstract][Full Text] [Related]
25. Treatment of leishmaniasis: a review and assessment of recent research. Elmahallawy EK; Agil A Curr Pharm Des; 2015; 21(17):2259-75. PubMed ID: 25543123 [TBL] [Abstract][Full Text] [Related]
26. Recent patents in the treatment and prevention of leishmaniasis. Shahid SK Pharm Pat Anal; 2023 Sep; 12(5):237-248. PubMed ID: 38063376 [TBL] [Abstract][Full Text] [Related]
27. Leishmaniasis and various immunotherapeutic approaches. Taslimi Y; Zahedifard F; Rafati S Parasitology; 2018 Apr; 145(4):497-507. PubMed ID: 27974063 [TBL] [Abstract][Full Text] [Related]
28. Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis. Duarte MC; Lage DP; Martins VT; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Goulart LR; Soto M; Tavares CA; Coelho EA Rev Soc Bras Med Trop; 2016; 49(4):398-407. PubMed ID: 27598624 [TBL] [Abstract][Full Text] [Related]
30. Leishmaniasis in humans: drug or vaccine therapy? Ghorbani M; Farhoudi R Drug Des Devel Ther; 2018; 12():25-40. PubMed ID: 29317800 [TBL] [Abstract][Full Text] [Related]
31. Antileishmanial Drug Discovery: Synthetic Methods, Chemical Characteristics, and Biological Potential of Quinazolines and its Derivatives. Sahu A; Kumar D; Agrawal RK Antiinflamm Antiallergy Agents Med Chem; 2017; 16(1):3-32. PubMed ID: 28464778 [TBL] [Abstract][Full Text] [Related]
32. Parasite candidate vaccines: a warning from polymorphic Leishmania populations. Guerbouj S; Guizani I; Victoir K; Le Ray D; Dujardin JC Parasitol Today; 2000 Jun; 16(6):265. PubMed ID: 10827439 [No Abstract] [Full Text] [Related]
33. Vaccine candidates for leishmaniasis: a review. Nagill R; Kaur S Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175 [TBL] [Abstract][Full Text] [Related]
34. Immunotherapy in treatment of leishmaniasis. Akbari M; Oryan A; Hatam G Immunol Lett; 2021 May; 233():80-86. PubMed ID: 33771555 [TBL] [Abstract][Full Text] [Related]
35. Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis. de Mendonça LZ; Resende LA; Lanna MF; Aguiar-Soares RD; Roatt BM; Castro RA; Batista MA; Silveira-Lemos D; Gomes Jde A; Fujiwara RT; Rezende SA; Martins-Filho OA; Corrêa-Oliveira R; Dutra WO; Reis AB; Giunchetti RC Parasit Vectors; 2016 Aug; 9(1):472. PubMed ID: 27577735 [TBL] [Abstract][Full Text] [Related]
37. Current status and perspectives of the immunotherapy of leishmaniasis. El-On J Isr Med Assoc J; 2009 Oct; 11(10):623-8. PubMed ID: 20077951 [TBL] [Abstract][Full Text] [Related]
38. Dendritic Cells and Leishmania Infection: Adding Layers of Complexity to a Complex Disease. Feijó D; Tibúrcio R; Ampuero M; Brodskyn C; Tavares N J Immunol Res; 2016; 2016():3967436. PubMed ID: 26904694 [TBL] [Abstract][Full Text] [Related]
39. Drugs against leishmaniasis: a synergy of technology and partnerships. Davis AJ; Murray HW; Handman E Trends Parasitol; 2004 Feb; 20(2):73-6. PubMed ID: 14747020 [TBL] [Abstract][Full Text] [Related]